Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449 is registered in ClinicalTrials.gov with Durham VA Medical Center as lead sponsor.

NCT NCT03881449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03881449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole
Lead sponsor
Durham VA Medical Center
Phase
Phase 4
Overall status
Unknown status
Start date
April 4, 2019
Completion date
November 30, 2021
Enrollment
46 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bi-polar disorder, major depressive disorder, schizo affective disorder, schizophrenia